6,405 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund purchased a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) in the 3rd quarter, Holdings Channel.com reports. The firm purchased 6,405 shares of the biotechnology company’s stock, valued at approximately $543,000.

Other institutional investors have also added to or reduced their stakes in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in BioMarin Pharmaceutical by 7.7% during the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 53,503 shares of the biotechnology company’s stock valued at $4,434,000 after buying an additional 3,832 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of BioMarin Pharmaceutical by 17.9% in the 2nd quarter. Rhumbline Advisers now owns 192,672 shares of the biotechnology company’s stock valued at $15,967,000 after purchasing an additional 29,286 shares during the last quarter. Hancock Whitney Corp bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $208,000. Victory Capital Management Inc. lifted its stake in shares of BioMarin Pharmaceutical by 3.3% in the 3rd quarter. Victory Capital Management Inc. now owns 735,470 shares of the biotechnology company’s stock valued at $62,346,000 after purchasing an additional 23,652 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its stake in shares of BioMarin Pharmaceutical by 99.0% in the 2nd quarter. Ensign Peak Advisors Inc now owns 90,326 shares of the biotechnology company’s stock valued at $7,485,000 after purchasing an additional 44,936 shares during the last quarter. Hedge funds and other institutional investors own 96.26% of the company’s stock.

Insider Buying and Selling

In related news, EVP Jeffrey Robert Ajer sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 2nd. The stock was sold at an average price of $86.12, for a total transaction of $258,360.00. Following the transaction, the executive vice president now directly owns 41,088 shares in the company, valued at approximately $3,538,498.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP Jeffrey Robert Ajer sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 2nd. The stock was sold at an average price of $86.12, for a total transaction of $258,360.00. Following the transaction, the executive vice president now directly owns 41,088 shares in the company, valued at approximately $3,538,498.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jean Jacques Bienaime sold 1,500 shares of the business’s stock in a transaction on Monday, October 31st. The stock was sold at an average price of $86.55, for a total value of $129,825.00. Following the transaction, the chief executive officer now owns 322,824 shares in the company, valued at $27,940,417.20. The disclosure for this sale can be found here. Insiders have sold a total of 44,380 shares of company stock worth $4,706,718 in the last ninety days. 1.75% of the stock is owned by insiders.

BioMarin Pharmaceutical Trading Up 2.1 %

Shares of NASDAQ:BMRN opened at $113.82 on Wednesday. BioMarin Pharmaceutical Inc. has a 12-month low of $70.73 and a 12-month high of $114.80. The business’s fifty day simple moving average is $103.98 and its 200-day simple moving average is $93.89. The company has a market capitalization of $21.11 billion, a PE ratio of 271.00 and a beta of 0.36. The company has a current ratio of 5.15, a quick ratio of 3.54 and a debt-to-equity ratio of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last announced its quarterly earnings results on Wednesday, October 26th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.04. BioMarin Pharmaceutical had a return on equity of 2.50% and a net margin of 4.18%. The business had revenue of $505.30 million for the quarter, compared to the consensus estimate of $516.03 million. During the same period last year, the business posted ($0.03) EPS. The business’s revenue was up 23.6% compared to the same quarter last year. As a group, equities research analysts predict that BioMarin Pharmaceutical Inc. will post 0.87 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BMRN has been the subject of a number of research analyst reports. Wedbush raised their price target on BioMarin Pharmaceutical from $74.00 to $83.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 11th. Evercore ISI raised their price target on BioMarin Pharmaceutical to $130.00 in a research note on Friday, December 2nd. Royal Bank of Canada raised their price target on BioMarin Pharmaceutical from $90.00 to $95.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 13th. Credit Suisse Group decreased their price target on BioMarin Pharmaceutical from $111.00 to $110.00 and set an “outperform” rating for the company in a research note on Thursday, October 27th. Finally, StockNews.com began coverage on BioMarin Pharmaceutical in a research note on Wednesday, October 12th. They set a “buy” rating for the company. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $120.12.

BioMarin Pharmaceutical Profile

(Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.